MEIRAGTX HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.4 USD | +2.09% |
|
-2.00% | -37.32% |
Presenter SpeechAlexandria Forbes (Executives)Thank you very much for inviting me to speak at ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.4
USD
Average target price
21.2
USD
Spread / Average Target
+381.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.32% | 283M | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| -19.80% | 20.43B | |
| -16.19% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +66.67% | 15.19B | |
| +2.13% | 13.54B | |
| +119.39% | 10.96B |
- Stock Market
- Equities
- MGTX Stock
- News MeiraGTx Holdings plc
- Transcript : MeiraGTx Holdings plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02
